trabodenoson manufacturers
- Trabodenoson
-
- $31.00
-
2026-08-08
- CAS:871108-05-3
- Purity: 99.94%
- Supply Ability: 10g
|
| | trabodenoson Basic information |
| Product Name: | trabodenoson | | Synonyms: | trabodenoson;((2R,3S,4R,5R)-5-(6-(CYCLOPENTYLAMINO)-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL)METHYL NITRATE;Adenosine, N-cyclopentyl-, 5'-nitrate;INO-8875;INNO-8875;N-Cyclopentyladenosine 5'-nitrate;PJ 875;Trabodenoson, 10 mM in DMSO | | CAS: | 871108-05-3 | | MF: | C15H20N6O6 | | MW: | 380.36 | | EINECS: | | | Product Categories: | | | Mol File: | 871108-05-3.mol |  |
| | trabodenoson Chemical Properties |
| Boiling point | 691.2±65.0 °C(Predicted) | | density | 1.87±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | DMSO: soluble | | form | A crystalline solid | | pka | 12.99±0.70(Predicted) | | color | White to yellow |
| | trabodenoson Usage And Synthesis |
| Uses | Trabodenoson alters ECM turnover by TM cells and increases conventional outflow facility, which accounts for its ability to lower IOP in young and aged mice. | | in vivo | Trabodenoson (6.0%), demonstrating an average IOP drop of 2.45 ± 0.38 mm Hg in young mice over 7 days (downregulation)[1].
Topical trabodenoson significantly upregulates nestin expression in the ONH of induced eyes compared with vehicle-treated no-induced eyes[2].
Trabodenoson-treated eyes have significantly reduced optic nerve (ON) edema compared with vehicle-treated eyes. RGC counts are higher in Trabodenoson-treated eyes compared to vehicle (74% versus 47% of the contralateral eye)[2].
| Animal Model: | Young (3-4 months old) and aged (12 months old)[1]. | | Dosage: | 3% or 6% in 10 μL. | | Administration: | Eye drop for 7 consecutive days. | | Result: | Decreased IOP. |
| Animal Model: | Rats[2]. | | Dosage: | 3%. | | Administration: | Topical delivery daily. | | Result: | Had significantly reduced optic nerve (ON) edema. |
|
| | trabodenoson Preparation Products And Raw materials |
|